A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
暂无分享,去创建一个
C. Leonardi | M. Suárez-Fariñas | D. Shortino | L. Parish | R. Matheson | J. Krueger | I. Cueto | Artemis Khacherian | Akanksha Gupta | J. Haddad | G. Vlasuk | E. Jacobson | Jonathan Haddad | Denise D Shortino
[1] Amy V. Lynch,et al. The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate , 2013 .
[2] P. Elliott,et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. , 2013, British journal of clinical pharmacology.
[3] Suyan Tian,et al. Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease , 2012, PloS one.
[4] Mayte Suárez-Fariñas,et al. Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.
[5] S. Chimenti,et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.
[6] N. J. Eungdamrong,et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. , 2010, The Journal of allergy and clinical immunology.
[7] Lisa C. Zaba,et al. Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.
[8] P. Elliott,et al. Sirtuins — novel therapeutic targets to treat age-associated diseases , 2008, Nature Reviews Drug Discovery.
[9] David Sinclair,et al. Sirtuins in mammals: insights into their biological function. , 2007, The Biochemical journal.
[10] Mayte Suárez-Fariñas,et al. Harshlight: a "corrective make-up" program for microarray chips , 2005, BMC Bioinformatics.
[11] G. Ashcroft,et al. Late cornified envelope family in differentiating epithelia--response to calcium and ultraviolet irradiation. , 2005, The Journal of investigative dermatology.
[12] R. Langley,et al. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. , 2004, Journal of the American Academy of Dermatology.
[13] L. Guarente,et al. The Sir2 family of protein deacetylases. , 2004, Annual review of biochemistry.
[14] S. Feldman,et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. , 2004, Journal of the American Academy of Dermatology.
[15] Zhijin Wu,et al. Preprocessing of oligonucleotide array data , 2004, Nature Biotechnology.
[16] C. MacKenzie,et al. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. , 1999, Advances in experimental medicine and biology.
[17] P. van de Putte,et al. Molecular characterization and evolution of the SPRR family of keratinocyte differentiation markers encoding small proline-rich proteins. , 1993, Genomics.
[18] C. Blyth,et al. Binomial Confidence Intervals , 1983 .